AIML Subsidiary NeuralCloud Signs Agreement With MyCor360+ to Integrate MaxYield(TM) into Next-Generation Cardiac Monitoring Device
The proposed collaboration supports NeuralCloud's strategy of expanding MaxYield through medical-device partnerships.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
AI/ML Innovations (AIMLF) subsidiary NeuralCloud signed a non-binding agreement with MyCor360+ to explore licensing MaxYield for a developing cardiac monitoring device. The proposed integration would add MaxYield's artificial-intelligence software for processing electrocardiogram (ECG) signals to MyCor360+'s hardware platform. MyCor360+ would oversee device development and commercialization through its manufacturing partner, while NeuralCloud would supply the software.
The parties intend to pursue a definitive software licensing agreement following further technical development and satisfaction of applicable regulatory requirements. Commercial implementation depends on further agreement, successful integration, technical readiness and required FDA clearances for both hardware and software. Neither product has FDA clearance for the proposed application, and the agreement does not commit the parties to commercial deployment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Agreement with MyCor360+ establishes a proposed path to integrate and license NeuralCloud's MaxYield software.
Negative
- Moderate pointNon-binding, early-stage agreement requires further agreement before any definitive commercial arrangement or deployment.
- Moderate pointRequired FDA clearances remain outstanding for both hardware and MaxYield software in the proposed application.
- Minor point. Forward-looking: it has not happened yet and may not happen.Successful technical integration and confirmed readiness remain conditions for implementing the contemplated licensing arrangement.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, ON / ACCESS Newswire / November 12, 2026 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company advancing artificial intelligence and neural-network-based technologies for digital health, is pleased to announce that its wholly owned subsidiary, NeuralCloud Solutions Inc. ("NeuralCloud"), has entered into a non-binding agreement with MyCor360+, a cardiac monitoring technology initiative developing a new medical device platform, to explore the integration and licensing of NeuralCloud's proprietary MaxYield™ ECG signal-processing technology.
The proposed collaboration is focused on incorporating MaxYield™ as the software intelligence layer within a cardiac monitoring device currently under development. The objective is to combine advanced ECG recording hardware with NeuralCloud's AI-powered signal-processing capabilities to support more efficient and detailed ECG analysis for clinical applications.
Under the proposed arrangement, MyCor360+ will oversee the development and commercialization of the device through its manufacturing partner, while NeuralCloud will provide its MaxYield™ technology for integration into the platform. The parties intend to pursue a definitive software licensing agreement following further technical development and satisfaction of applicable regulatory requirements.
Combining ECG Hardware with AI-Powered Signal Processing
Cardiac monitoring continues to evolve as healthcare providers seek technologies that can deliver high-quality ECG data, support efficient diagnostic workflows, and enable longer-duration monitoring outside traditional clinical settings.
MyCor360+ is developing a cardiac monitoring platform intended to bring together ECG recording hardware and advanced software capabilities within an integrated solution.
MaxYield™ is NeuralCloud's proprietary AI-based ECG signal-processing engine designed to improve signal clarity, reduce noise and artifacts, and identify and label key ECG waveform components, including P waves, QRS complexes, and T waves. The platform generates structured, machine-readable outputs, including waveform delineation and beat-level interval measurements, to support downstream ECG analysis and reporting workflows.
By incorporating MaxYield™ directly into the proposed cardiac monitoring platform, the parties aim to evaluate a combined hardware and software solution capable of providing cleaner, more detailed ECG data for use in cardiac monitoring applications.
Developing an Integrated Cardiac Monitoring Solution
MyCor360+ is developing a cellular-enabled cardiac monitoring device intended to support both traditional Holter monitoring and mobile cardiac telemetry ("MCT") applications. The proposed device is being designed as a disposable, single-use solution capable of recording cardiac activity for up to 14 days, with automated transmission of ECG data through cellular networks.
The planned technology is intended to address several limitations of conventional cardiac monitoring devices by simplifying the patient experience, reducing dependence on manual data transfers, and enabling more efficient access to recorded ECG information. Where cellular connectivity is temporarily unavailable, the system is being designed to retain recorded data for transmission once connectivity is restored.
The proposed platform will also include a streamlined clinician-facing portal for managing ECG recordings and supporting integration with existing healthcare workflows and electronic medical record systems. NeuralCloud's MaxYield™ technology is expected to provide the underlying AI-powered signal-processing capabilities, converting recorded ECG signals into cleaner, structured data for downstream analysis and reporting.
Together, the parties aim to develop a more integrated approach to ambulatory cardiac monitoring, combining convenient ECG acquisition, automated data transmission, and advanced signal processing within a unified workflow.
Esmat Naikyar, President of NeuralCloud Solutions Inc. and Chief Product Officer of AIML, commented:
"Cardiac monitoring technology is evolving rapidly, and there is growing demand for solutions that combine reliable ECG acquisition with intelligent signal processing. MaxYield was designed to address one of the fundamental challenges in ECG analysis: separating meaningful cardiac signals from noise while preserving detailed waveform information. This collaboration provides an opportunity to integrate that capability into a new cardiac monitoring platform and evaluate its potential to support more efficient and informative ECG analysis."
Advancing NeuralCloud's OEM Integration Strategy
The proposed collaboration supports NeuralCloud's broader strategy to expand the reach of MaxYield™ through partnerships with medical device developers, original equipment manufacturers ("OEMs"), and cardiac monitoring technology providers.
Rather than requiring hardware manufacturers to independently develop sophisticated ECG signal-processing algorithms, MaxYield™ is designed to provide an AI-powered software layer that can be incorporated into compatible devices and digital health platforms.
This approach allows NeuralCloud to focus on its core expertise in ECG signal interpretation while collaborating with partners responsible for hardware development, manufacturing, and device distribution.
Paul Duffy, Executive Chairman and CEO of AIML, commented: "This agreement reflects our continued efforts to establish MaxYield as a core signal-processing technology for the cardiac monitoring industry. By combining our AI capabilities with a developing cellular-enabled Holter and mobile cardiac telemetry platform, we see an opportunity to support a more seamless cardiac monitoring experience for patients and healthcare providers. This collaboration aligns with our broader strategy of integrating MaxYield directly into next-generation medical devices."
Next Steps and Regulatory Considerations
The parties expect to work toward technical coordination between NeuralCloud and MyCor360+'s manufacturing partner to evaluate the proposed integration of MaxYield™ into the developing device platform.
The collaboration remains at an early stage, and the agreement is non-binding. Any definitive commercial arrangement, software deployment, or product commercialization will be subject to further agreement between the parties, successful technical integration, and applicable regulatory requirements.
Neither MaxYield™ nor the MyCor360+ device has received FDA clearance for the proposed application. Implementation of the contemplated commercial licensing arrangement is subject to the required FDA clearances for the hardware and MaxYield™ software, as well as confirmation of technical readiness. The agreement does not constitute regulatory clearance, marketing authorization, or a commitment to commercial deployment.
About MyCor360+
MyCor360+ is a cardiac monitoring technology initiative focused on the development of a new ECG monitoring device platform. The initiative is working with a medical device manufacturing partner to develop an integrated hardware and software solution for future cardiac monitoring applications, subject to technical validation and applicable regulatory clearances.
About NeuralCloud Solutions Inc.
NeuralCloud Solutions Inc., a wholly owned subsidiary of AI/ML Innovations Inc., develops artificial intelligence and neural-network-based technologies for ECG signal analysis and cardiac software applications. Its platforms are designed to enhance ECG signal quality, support advanced waveform interpretation, enable arrhythmia analytics, and improve workflow efficiency across healthcare and research environments.
About AI/ML Innovations Inc.
AIML Innovations Inc. is a global technology company pioneering the use of artificial intelligence and neural networks to transform digital health. The Company's proprietary platforms leverage advanced signal processing and deep learning to convert complex biometric data into actionable clinical insights-supporting earlier diagnosis, personalized treatment, and more effective care.
AIML's shares trade on the Canadian Securities Exchange (CSE:AIML), the OTCQB Venture Market (AIMLF), and the Frankfurt Stock Exchange (FWB:42FB).
For detailed information, please see AIML's website at www.aiml.health or the Company's filed documents at www.sedarplus.ca.
AIML Contact:
Paul Duffy
Executive Chairman and CEO
ask@aiml-innovations.com
416-941-8900
Neither the CSE nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties, including statements regarding the proposed collaboration with MyCor360+ integration of MaxYield™ into cardiac monitoring hardware, device development, technical validation, definitive commercial agreements, regulatory submissions, FDA clearance, future commercialization, and the implementation of the Company's products and services. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including risks associated with product development, integration challenges, technical performance, regulatory review, manufacturing readiness, market acceptance, and the receipt of applicable regulatory approvals. There can be no assurance that the parties will enter into a definitive agreement or that the contemplated integration or commercialization will occur. Readers are cautioned that assumptions used in preparing forward-looking information may prove to be imprecise and that undue reliance should not be placed on forward-looking statements. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.
SOURCE: AI/ML Innovations Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does AI/ML Innovations' NeuralCloud agreement with MyCor360+ cover?
The non-binding agreement covers exploration of MaxYield software integration and licensing for MyCor360+'s developing cardiac monitoring device. MyCor360+ would oversee hardware development and commercialization through its manufacturing partner, while NeuralCloud would provide the ECG signal-processing software.
Does the NeuralCloud and MyCor360+ agreement authorize commercial deployment?
The agreement does not authorize or commit the parties to commercial deployment. Implementation requires further agreement, successful technical integration, confirmation of technical readiness and required FDA clearances for the hardware and MaxYield software. Neither has FDA clearance for the proposed application.